<DOC>
	<DOCNO>NCT02317562</DOCNO>
	<brief_summary>Primary objective : To assess efficacy I10E administer reduced maintenance dose sustain CIDP response initial 6-month treatment PRISM study . ( I10E-1302 ) . Secondary objective : To assess safety I10E patient population .</brief_summary>
	<brief_title>Efficacy Safety Study I10E Maintenance Treatment Patients With CIDP : Extension PRISM Study I10E-1302</brief_title>
	<detailed_description />
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<criteria>1 . Male female patient age 18 year . 2 . Responder patient complete last visit PRISM I10E1302 study define patient decrease ≥1 point adjust INCAT disability score baseline endofstudy ( EOS ) visit PRISM I10E1302 study . 3 . Covered national healthcare insurance system require local regulation . 4 . Written inform consent obtain prior studyrelated procedure . 1 . History severe allergic reaction serious adverse reaction Ig . 2 . Known hypersensitivity human Ig excipients I10E ( glycine polysorbate 80 ) . 3 . History cardiac insufficiency ( New York Heart Association ( NYHA ) III/IV ) , uncontrolled cardiac arrhythmia , unstable ischemic heart disease , uncontrolled hypertension . 4 . History venous thromboembolic disease , myocardial infarction cerebrovascular accident . 5 . Risk factor blood hyperviscosity cryoglobulinemia haematological malignancy monoclonal gammopathy . 6 . Body mass index ( BMI ) ≥40 kg/m² . 7 . Glomerular filtration rate &lt; 80 mL/min/1.73m² measure accord Modified Diet Renal Disease ( MDRD ) calculation . 8 . Any ongoing disease may cause chronic peripheral neuropathy , toxin exposure , dietary deficiency , uncontrolled diabetes , hyperthyroidism , cancer , systemic lupus erythematosus connective tissue disease , infection HIV , Hepatitis B Virus ( HBV ) Hepatitis C Virus ( HCV ) , Lyme disease , multiple myeloma , Waldenström 's macroglobulinaemia , amyloidosis , hereditary neuropathy . 9 . Woman positive result urine pregnancy test breastfeed woman woman childbearing potential without effective contraception . 10 . Any serious medical condition would interfere clinical assessment CIDP use I10E prevent patient comply protocol requirement . 11 . Increasing dosage introduction systemic corticosteroid therapy within last 3 month prior screen , dose high 10 mg daily prednisolone equivalent . Topical corticosteroid permit . 12 . Treatment within 12 month prior screen immunomodulatory immunosuppressant agent ( include limit cyclophosphamide , cyclosporine , interferonα , interferonβ1a , antiCD20 , alemtuzumab , aziathioprine , etanercept , mycophenolate mofetil methotrexate ) haemopoetic stem cell transplantation . 13 . Plasma exchange , blood product derivative administer within last 3 month prior screen . 14 . Anticipated poor compliance patient study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>Disimmune disease</keyword>
	<keyword>Neurology chronic disease</keyword>
	<keyword>Rare disease</keyword>
</DOC>